{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:23:49Z","timestamp":1790036629341,"version":"4.0.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.14283\/jpad.2022.85","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:18:36Z","timestamp":1665404316000},"page":"569-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU\/US CTAD Task Force"],"prefix":"10.1016","volume":"9","author":[{"given":"Davide","family":"Angioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Delrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pontecorvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bozeat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Largent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mattke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Gutierrez Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Baldivieso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.R.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-J.","family":"Ousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.14283\/jpad.2022.85_bib1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.14283\/jpad.2022.85_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/WAD.0b013e3181a6bebc","article-title":"Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors","volume":"23","author":"Bradford","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"10.14283\/jpad.2022.85_bib3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.14283\/jpad.2022.85_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-021-00451-6","article-title":"A blood-based diagnostic test incorporating plasma A\u03b242\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis","volume":"16","author":"West","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"4","key":"10.14283\/jpad.2022.85_bib6","doi-asserted-by":"crossref","first-page":"e228392","DOI":"10.1001\/jamanetworkopen.2022.8392","article-title":"Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment","volume":"5","author":"Hu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.14283\/jpad.2022.85_bib7","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.14283\/jpad.2022.85_bib8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-Head Comparison of 8 Plasma Amyloid-\u03b2 42\/40 Assays in Alzheimer Disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.14283\/jpad.2022.85_bib9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","article-title":"Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes","volume":"78","author":"Mielke","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"10.14283\/jpad.2022.85_bib11","doi-asserted-by":"crossref","first-page":"e20200861","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J Exp Med"},{"issue":"8","key":"10.14283\/jpad.2022.85_bib12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40478-021-01307-2","article-title":"Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels","volume":"10","author":"Wennstr\u00f6m","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"10.14283\/jpad.2022.85_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/alz.12395","article-title":"Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau","volume":"18","author":"Janelidze","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.14283\/jpad.2022.85_bib15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.14283\/jpad.2022.85_bib16","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","article-title":"The accuracy and robustness of plasma biomarker models for amyloid PET positivity","volume":"14","author":"Benedet","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2022.85_bib18","article-title":"Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models","author":"Cullen","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.14283\/jpad.2022.85_bib19","doi-asserted-by":"crossref","first-page":"fcab008","DOI":"10.1093\/braincomms\/fcab008","article-title":"Detection of \u03b2-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers","volume":"3","author":"Tosun","year":"2021","journal-title":"Brain Commun"},{"issue":"7691","key":"10.14283\/jpad.2022.85_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.14283\/jpad.2022.85_bib21","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","article-title":"Validation of Plasma Amyloid-\u03b2 42\/40 for Detecting Alzheimer Disease Amyloid Plaques","volume":"98","author":"Li","year":"2022","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.85_bib22","article-title":"Comparative analytical performance of multiple plasma A\u03b242 and A\u03b240 assays and their ability to predict positron emission tomography amyloid positivity","author":"Zicha","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.85_bib23","article-title":"Plasma ratio of phospho- to non-phospho-tau at threonine 217 identifies brain amyloid burden as measured by quantitative amyloid PET in the PARIS sub-study of IDEAS","author":"Meyer","year":"2022","journal-title":"AAIC Scientific Session"},{"key":"10.14283\/jpad.2022.85_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2022.85_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01675-8","article-title":"Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression","author":"Tsiknia","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.14283\/jpad.2022.85_bib26","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1212\/WNL.0000000000200358","article-title":"Effect of Race on Prediction of Brain Amyloidosis by Plasma A\u03b242\/A\u03b240, Phosphorylated Tau, and Neurofilament Light","volume":"99","author":"Schindler","year":"2022","journal-title":"Neurology"},{"issue":"3","key":"10.14283\/jpad.2022.85_bib27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/alz.12205","article-title":"APOE alleles' association with cognitive function differs across Hispanic\/Latino groups and genetic ancestry in the study of Latinos-investigation of neurocognitive aging (HCHS\/SOL)","volume":"17","author":"Granot-Hershkovitz","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321984","article-title":"Apolipoprotein E \u03b54 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis","volume":"31","author":"Crean","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.14283\/jpad.2022.85_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","article-title":"The Role of Biomarkers in Alzheimer's Disease Drug Development","volume":"1118","author":"Cummings","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.14283\/jpad.2022.85_bib30","unstructured":"Sperling RA, Johnson KA, Zhou J, Irizarry MC, Dhadda S, Kramer LD, Li D, Li P, Swanson CJ, West T, Yarasheski KE, Kirmess KM, Meyer MR, Braunstein JB, Rissman RA, Rafii M, Grill J, Raman R, Sethuraman G, Donohue MC, Langford O, Aisen PS. on behalf of the AHEAD 3 45 Study Team. Introduction of plasma biomarker screening for the AHEAD 3 45 Study. Clinical Trials on Alzheimer's Disease Taskforce meeting, 31 May 2022."},{"key":"10.14283\/jpad.2022.85_bib31","unstructured":"Sims JR. Plasma Biomarkers in Screening: Lilly Trials. Clinical Trials on Alzheimer's Disease Taskforce meeting, 31 May 2022."},{"key":"10.14283\/jpad.2022.85_bib32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cca.2021.05.011","article-title":"The PrecivityADTM test: Accurate and reliable LC-MS\/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis","volume":"519","author":"Kirmess","year":"2021","journal-title":"Clin Chim Acta"},{"key":"10.14283\/jpad.2022.85_bib33","unstructured":"Bittner T. Blood-based prescreening for SKYLINE. Clinical Trials on Alzheimer's Disease Taskforce meeting, 31 May 2022."},{"issue":"1","key":"10.14283\/jpad.2022.85_bib34","doi-asserted-by":"crossref","first-page":"e14408","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer's disease","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"10.14283\/jpad.2022.85_bib36","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.14283\/jpad.2022.85_bib37","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"10.14283\/jpad.2022.85_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13195-022-01023-6","article-title":"Correction: Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217","volume":"14","author":"Groot","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","article-title":"Serum neurofilament light levels in normal aging and their association with morphologic brain changes","volume":"11","author":"Khalil","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.14283\/jpad.2022.85_bib41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.14283\/jpad.2022.85_bib42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.14283\/jpad.2021.36","article-title":"Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU\/US CTAD Task Force","volume":"8","author":"Kaye","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2022.85_bib43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.trci.2018.04.003","article-title":"Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials","volume":"4","author":"Gold","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"10.14283\/jpad.2022.85_bib44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.14283\/jfa.2020.51","article-title":"Intrinsic Capacitiy Monitoring by Digital Biomarkers in Integrated Care for Older People (ICOPE)","volume":"10","author":"Piau","year":"2021","journal-title":"J Frailty Aging"},{"issue":"6","key":"10.14283\/jpad.2022.85_bib45","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/S2666-7568(22)00097-6","article-title":"Implementation of the WHO integrated care for older people (ICOPE) programme in clinical practice: a prospective study","volume":"3","author":"Tavassoli","year":"2022","journal-title":"The Lancet Healthy Longevity"},{"issue":"4","key":"10.14283\/jpad.2022.85_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.14283\/jpad.2022.85_bib47","first-page":"2","article-title":"Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment","volume":"8","author":"Hlavka","year":"2019","journal-title":"Rand Health Q"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib48","first-page":"e12081","article-title":"Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times","volume":"12","author":"Mattke","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"issue":"9","key":"10.14283\/jpad.2022.85_bib49","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacr.2012.05.005","article-title":"Geographic and sociodemographic disparities in PET use by Medicare beneficiaries with cancer","volume":"9","author":"Onega","year":"2012","journal-title":"J Am Coll Radiol"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamaneurol.2017.2954","article-title":"Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults","volume":"75","author":"Mozersky","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.14283\/jpad.2022.85_bib51","doi-asserted-by":"crossref","first-page":"e12150","DOI":"10.1002\/dad2.12150","article-title":"Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know","volume":"13","author":"Erickson","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"9","key":"10.14283\/jpad.2022.85_bib52","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/alz.12129","article-title":"A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment","volume":"16","author":"Lingler","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.14283\/jpad.2022.85_bib53","doi-asserted-by":"crossref","first-page":"e0229137","DOI":"10.1371\/journal.pone.0229137","article-title":"Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results","volume":"15","author":"Largent","year":"2020","journal-title":"PLoS One"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:11:08Z","timestamp":1737339068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724002668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2274580724002668"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2022.85","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU\/US CTAD Task Force","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2022.85","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}